Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-25T06:22:19.319Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Comparison of Fluoxetine and Amitriptyline in Depressed Out-patients

Published online by Cambridge University Press:  02 January 2018

J. P. R. Young ,
A. Coleman  and
M. H. Lader
J. P. R. Young
Affiliation:
St Thomas's Hospital, London
A. Coleman
Affiliation:
Queen Mary's Hospital, Roehampton
M. H. Lader*
Affiliation:
Institute of Psychiatry
*
Department of Pharmacology, Institute of Psychiatry, De Crespigny Park, London SE5 8AF
Get access Rights & Permissions [Opens in a new window]

Extract

Fluoxetine, a selective serotonin uptake inhibitor (mean dose 73 mg each morning) was compared with amitriptyline (mean dose 122 mg at night) in a double-blind study of 64 depressed out-patients. Fifty patients completed the 6-week trial. The drugs did not differ with respect to psychiatrists' ratings, but amitriptyline was slightly superior with respect to patients' ratings. The amitriptyline-treated group had complaints of dry mouth and dizziness on standing; the fluoxetine-treated group of sleep disturbances, nausea, and headaches.

Type
Papers
Information
The British Journal of Psychiatry , Volume 151 , Issue 3 , September 1987 , pp. 337 - 340
Copyright
Copyright © Royal College of Psychiatrists, 1987 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chouinard, G. (1985) A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of out-patients with major depressive disorder. Journal of Clinical Psychiatry, 46, 32–37.Google ScholarPubMed
Feighner, J. P. (1985) A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. Journal of Clinical Psychiatry, 46, 369–372.Google ScholarPubMed
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57–63.CrossRefGoogle ScholarPubMed
Fuller, R. W., Snoddy, H. D., Perry, K. W., Bymaster, F. P. & Wong, D. T. (1978) importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin-comparison of fluoxetine and chlorimipramine. Biochemical Pharmacology, 27, 193–198.CrossRefGoogle ScholarPubMed
Lemberger, L., Fuller, R. W. & Zerbe, R. L. (1985) Use of specific serotonin uptake inhibitors as antidepressants. Clinical Neuropharmacology, 8, 299–317.CrossRefGoogle ScholarPubMed
Peroutka, S. J. & Snyder, S. H. (1980) Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science, 210, 88–90.CrossRefGoogle ScholarPubMed
Stark, P. & Hardison, C. D. (1985) A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. Journal of Clinical Psychiatry, 46, 53–58.Google ScholarPubMed
Stark, P. & Hardison, C. D., Fuller, R. W. & Wong, D. T. (1985) The pharmacologic profile of fluoxetine. Journal of Clinical Psychiatry, 46, 7–13.Google ScholarPubMed
Wernicke, J. F. (1985) The side effect profile and safety of fluoxetine. Journal of Clinical Psychiatry, 46, 59–67.Google ScholarPubMed
Willner, P. (1985) Antidepressants and serotonergic neurotransmission: an integrative review. Psychopharmacology, 85, 387–404.CrossRefGoogle ScholarPubMed
Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L. & Molloy, B. B. (1974) A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenyl-propylamine. Life Science, 15, 471–479.CrossRefGoogle Scholar
Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L. & Molloy, B. B., Bymaster, F. P., Horng, J. S. & Molloy, B. B. (1975) A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Journal of Pharmacology and Experimental Therapeutics, 193, 804–811.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.